Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New therapeutic issues in CLL

E Montserrat1

  • 1Department of Haematology, Hospital Clinic, Barcelona, Spain.

Hematology and Cell Therapy
|February 21, 1998
PubMed
Summary
This summary is machine-generated.

The treatment for chronic lymphocytic leukemia (CLL) has advanced with new chemotherapy and biotherapy options, including monoclonal antibodies and stem cell transplants. Further research is needed to establish the role of transplants in managing CLL.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2020
Same author

Is chronic lymphocytic leukemia curable? A clinical case relapsing 21 years after allogeneic stem-cell transplantation.

Bone marrow transplantation·2020
Same author

Somatic CLL mutations occur at multiple distinct hematopoietic maturation stages: documentation and cautionary note regarding cell fraction purity.

Leukemia·2017
Same author

appendix 6: Chronic lymphocytic leukaemia: eUpdate published online September 2016 (http://www.esmo.org/Guidelines/Haematological-Malignancies).

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same author

Interferon alpha-2b for Essential Thrombocythaemia: Results in 13 Previously Untreated Patients.

Leukemia & lymphoma·2016
Same author

Chronic Lymphocytic Leukemia in Younger Adults: Preliminary Results of a Study Based on 454 Patients-IWCLL/Working Group.

Leukemia & lymphoma·2016
Same journal

The place of instruments in the scientific work of Marcel Bessis (1917-1994): the electron microscope and the ektacytometer.

Hematology and cell therapy·2001
Same journal

In memory of Marcel Bessis.

Hematology and cell therapy·2001
Same journal

Emerging therapies and future directions in CLL--monoclonal antibodies, vaccines and gene therapy.

Hematology and cell therapy·2000
Same journal

Emerging therapies and future directions in chronic lymphocytic leukaemia--chemotherapy.

Hematology and cell therapy·2000
Same journal

Chronic lymphocytic leukemia . Clinical oral poster session.

Hematology and cell therapy·2000
Same journal

Current therapy for CLL.

Hematology and cell therapy·2000
See all related articles

Area of Science:

  • Hematology
  • Oncology

Background:

  • Chronic lymphocytic leukemia (CLL) treatment has seen significant advancements.
  • The therapeutic landscape has expanded with novel agents and approaches.

Framework:

  • New cytotoxic agents, particularly purine analogues, demonstrate high response rates, sometimes achieving molecular remissions.
  • Combination chemotherapy regimens utilizing purine analogues with other drugs like cyclophosphamide, platinum, and ara-C are being explored.

Implementation:

  • Biotherapy, including vaccines and monoclonal antibodies, shows promise.
  • Monoclonal antibodies, such as CAMPATH 1H, have proven effective in CLL treatment, yielding response rates comparable to purine analogues.
  • Hematopoietic stem cell transplantation is increasingly utilized for young patients with high-risk CLL.

Related Experiment Videos

Implications:

  • The efficacy of purine analogues in combination regimens offers new therapeutic strategies.
  • Monoclonal antibodies provide a viable biotherapy option for CLL.
  • The role of stem cell transplantation in CLL management requires further investigation through prospective, controlled studies.